{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:28:40Z","timestamp":1788571720799,"version":"build-2803163510"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR305423"],"award-info":[{"award-number":["NIHR305423"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","award":["NIHR206942"],"award-info":[{"award-number":["NIHR206942"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RRCOER-Jun24\/100004"],"award-info":[{"award-number":["RRCOER-Jun24\/100004"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijrobp.2026.03.004","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T08:49:25Z","timestamp":1773391765000},"page":"64-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Constraints, Cumulative Doses, and Toxicity Outcomes in Glioma Reirradiation: A Systematic Review and Radiobiological Comparison From the Reirradiation Collaborative Group (ReCOG)"],"prefix":"10.1016","volume":"126","author":[{"given":"Finbar","family":"Slevin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang Scott","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin S.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette J.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish A.","family":"Butala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thankamma","family":"Ajithkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0658-6455","authenticated-orcid":false,"given":"Louise","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2026.03.004_bib0001","article-title":"Treatment options for progression or recurrence of glioblastoma: A network meta-analysis","volume":"5","author":"McBain","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13014-021-01767-9","article-title":"Current status and recent advances in reirradiation of glioblastoma","volume":"16","author":"Minniti","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0003","first-page":"144","article-title":"Re-irradiation for recurrent high-grade gliomas: A systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis","volume":"6","author":"Shanker","year":"2019","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0004","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): A systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.critrevonc.2018.03.024","article-title":"Re-irradiation as salvage treatment in recurrent glioblastoma: A comprehensive literature review to provide practical answers to frequently asked questions","volume":"126","author":"Scoccianti","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0007","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.prro.2025.04.003","article-title":"Practice patterns of reirradiation for brain and spinal tumors\u2014An international survey from the Reirradiation Collaborative Group (ReCOG)","volume":"15","author":"Chen","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0008","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ijrobp.2009.11.058","article-title":"Reirradiation of large-volume recurrent glioma with pulsed reduced-dose-rate radiotherapy","volume":"79","author":"Adkison","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0009","article-title":"An international expert survey on the indications and practice of radical thoracic reirradiation for non-small cell lung cancer","volume":"6","author":"Rulach","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0010","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.adro.2019.05.007","article-title":"The special medical physics consult process for reirradiation patients","volume":"4","author":"Paradis","year":"2019","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0011","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1016\/S1470-2045(22)00447-8","article-title":"European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: Definition, reporting, and clinical decision making","volume":"23","author":"Andratschke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0012","unstructured":"Murray L, Shen C, Rosen B. PROSPERO international prospective register of systematic reviews: Constraints, cumulative doses and toxicity outcomes in glioma reirradiation: A systematic review. PROSPERO. https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024575556. Accessed September 13, 2025."},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0013","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Higgins","year":"2024"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0014","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111030","article-title":"Reirradiation dose constraints in clinical practice: Results of an international survey","volume":"210","author":"Stroom","year":"2025","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0016","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.ijrobp.2025.03.002","article-title":"Reirradiation special medical physics consultations: Lessons learned from nearly 3000 courses of treatment","volume":"122","author":"Paradis","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0017","unstructured":"Institute of Health Economics (IHE). Quality appraisal of case series studies checklist. Institute of Health Economics; 2014. http:\/\/www.ihe.ca\/research-programs\/rmd\/cssqac\/cssqac-about. Accessed September 13, 2025."},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.radonc.2018.05.001","article-title":"Radiation dose constraints for organs at risk in neuro-oncology; the European Particle Therapy Network consensus","volume":"128","author":"Lambrecht","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0019","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.ijrobp.2007.08.015","article-title":"Reirradiation tolerance of the human brain","volume":"70","author":"Mayer","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0020","first-page":"48","article-title":"Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma","volume":"2","author":"Back","year":"2015","journal-title":"Neurooncol Pract"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s11060-020-03526-4","article-title":"Randomized prospective trial of fractionated stereotactic radiosurgery with chemotherapy versus chemotherapy alone for bevacizumab-resistant high-grade glioma","volume":"148","author":"Bergman","year":"2020","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0022","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s11060-022-04011-w","article-title":"Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma","volume":"158","author":"Breen","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0023","doi-asserted-by":"crossref","first-page":"4604","DOI":"10.3390\/cancers14194604","article-title":"Safety of inhomogeneous dose distribution IMRT for high-grade glioma reirradiation: A prospective phase I\/II trial (GLIORAD TRIAL)","volume":"14","author":"Ciammella","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0024","doi-asserted-by":"crossref","first-page":"566","DOI":"10.5603\/rpor.102820","article-title":"Reirradiation of gliomas with hypofractionated stereotactic radiotherapy: Efficacy and tolerance analysis at a single center","volume":"29","author":"Gonz\u00e1lez","year":"2024","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00066-023-02172-9","article-title":"Reirradiation with radiosurgery or stereotactic fractionated radiotherapy in association with regorafenib in recurrent glioblastoma","volume":"200","author":"Gregucci","year":"2024","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0026","first-page":"vdae073","article-title":"Pulsed reduced-dose rate re-irradiation for patients with recurrent grade 2 gliomas","volume":"6","author":"Harari","year":"2024","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.jocn.2025.111150","article-title":"Stereotactic radiosurgery for recurrent high-grade gliomas","volume":"135","author":"Kite","year":"2025","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0028","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13014-017-0930-9","article-title":"Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system","volume":"12","author":"Krauze","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0029","first-page":"vdaf004","article-title":"Fractionated reirradiation of recurrent high-grade gliomas: Safety with higher reirradiation dose and larger targets","volume":"7","author":"LeCompte","year":"2025","journal-title":"Neurooncol Adv"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0030","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11060-014-1363-z","article-title":"Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab","volume":"117","author":"Magnuson","year":"2014","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0031","first-page":"e1788","article-title":"Concurrent immunotherapy and re-irradiation utilizing stereotactic body radiotherapy for recurrent high-grade gliomas","volume":"6","author":"Mahase","year":"2023","journal-title":"Cancer Rep (Hoboken)"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0032","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11060-023-04398-0","article-title":"Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme","volume":"164","author":"Mantica","year":"2023","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0033","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.prro.2022.12.006","article-title":"A prospective study of conventionally fractionated dose constraints for reirradiation of primary brain tumors in adults","volume":"13","author":"McGovern","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0034","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2017.09.039","article-title":"Toxicity and efficacy of re-irradiation of high-grade glioma in a phase I dose- and volume escalation trial","volume":"125","author":"M\u00f8ller","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/1748-717X-8-287","article-title":"Analysis of equivalent uniform dose (EUD) and conventional radiation treatment parameters after primary and re-irradiation of malignant glioma","volume":"8","author":"Niyazi","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0036","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s11060-018-2989-z","article-title":"Bevacizumab and re-irradiation for recurrent high grade gliomas: Does sequence matter?","volume":"140","author":"Palmer","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0037","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.3390\/cancers16213652","article-title":"Efficacy and low toxicity of normo-fractionated re-irradiation with combined chemotherapy for recurrent glioblastoma-an analysis of treatment response and failure","volume":"16","author":"Pepper","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0038","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.adro.2018.06.005","article-title":"Re-irradiation for malignant glioma: Toward patient selection and defining treatment parameters for salvage","volume":"3","author":"Shen","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0039","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s11060-016-2059-3","article-title":"Phase I trial of panobinostat and fractionated stereotactic re-irradiation therapy for recurrent high grade gliomas","volume":"127","author":"Shi","year":"2016","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11060-017-2709-0","article-title":"Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment","volume":"137","author":"Shi","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0041","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.019","article-title":"Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas","volume":"132","author":"Song","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0042","first-page":"132","article-title":"High-dose re-irradiation of intracranial lesions \u2013 Efficacy and safety including dosimetric analysis based on accumulated EQD2Gy dose EQD calculation","volume":"27","author":"Stiefel","year":"2021","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0043","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11060-024-04643-0","article-title":"Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: A feasible option for patients with large-volume relapse","volume":"168","author":"Tong","year":"2024","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0044","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.22.00164","article-title":"NRG Oncology\/RTOG1205: A randomized phase II trial of concurrent bevacizumab and reirradiation versus bevacizumab alone as treatment for recurrent glioblastoma","volume":"41","author":"Tsien","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0045","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.ijrobp.2006.04.062","article-title":"Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma","volume":"66","author":"Wurm","year":"2006","journal-title":"Int J Rad Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0046","unstructured":"Electronic Medicines Compedium. Avastin 25mg\/ml concentrate for solution for infusion. Healthcare Professional SmPC. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/3885\/smpc. Accessed January 31, 2026."},{"issue":"3 suppl","key":"10.1016\/j.ijrobp.2026.03.004_bib0047","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0048","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.clon.2019.06.007","article-title":"The linear-quadratic model and implications for fractionation","volume":"31","author":"Brand","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0049","doi-asserted-by":"crossref","first-page":"S909","DOI":"10.1016\/S0167-8140(23)09134-X","article-title":"Reirradiation versus systemic therapy for recurrent high-grade glioma: A systematic review","volume":"182","author":"Marwah","year":"2023","journal-title":"Radiother oncol"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ijrobp.2020.08.013","article-title":"Single- and multifraction stereotactic radiosurgery dose\/volume tolerances of the brain","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"10.1016\/j.ijrobp.2026.03.004_bib0051","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ijrobp.2009.02.091","article-title":"Radiation dose-volume effects in the brain","volume":"76","author":"Lawrence","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0052","unstructured":"Verhoeff JJC. A multi-center, randomized, open label, phase III, non-inferiority study to compare the efficacy of re-irradiation schedules in glioma (RISinG). Trial protocol (December 2018)."},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0053","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-078926","article-title":"Brain Re-Irradiation Or Chemotherapy: A phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma (BRIOChe)\u2014Protocol for a multi-centre open-label randomised trial","volume":"14","author":"Hudson","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijrobp.2026.03.004_bib0054","unstructured":"A safety and efficacy trial of reirradiation dose escalation in thoracic cancers: Re-evaluating previous dose and allowing increasing recovery (REPAIR). 2024. https:\/\/clinicaltrials.gov\/study\/NCT06558175. Accessed November 20, 2025."}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004864?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301626004864?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:34:41Z","timestamp":1786520081000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301626004864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0360301626004864"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.004","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Constraints, Cumulative Doses, and Toxicity Outcomes in Glioma Reirradiation: A Systematic Review and Radiobiological Comparison From the Reirradiation Collaborative Group (ReCOG)","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2026.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}